Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT07524946 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.

Sponsor

Bausch Health Americas, Inc.

Collaborators

[object Object]